Payment overview · 2025
General Payments
$287.41
15 reported records · 7 companies
Healthcare provider profile · identity verified
Aaron K Mruk, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BUFFALO, NY · NPI 1215508213
Verified facts
What the public records show
CMS Open Payments records show Aaron K Mruk, FNP received $287.41 in general payments during 2025 across 15 reported records.
GlaxoSmithKline, LLC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.67 | 21.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.40 | 20.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.44 | 19.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.99 | 13.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.87 | 10.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.98 | 7.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.06 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $287.41 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.67 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.40 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.99 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.87 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 117 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 176 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
176 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 469 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 144 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 431 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 375 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 100 |
| Omeprazole | Omeprazole | 202 | 73 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 176 | 41 |
| Ibuprofen | Ibuprofen | 148 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 44 |
| Lisinopril | Lisinopril | 127 | 49 |
| Benazepril Hcl | Benazepril Hcl | 121 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 35 |
| Jardiance | Empagliflozin | 117 | 29 |
| Pregabalin | Pregabalin | 115 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 34 |
| Furosemide | Furosemide | 102 | 31 |
| Metformin Hcl | Metformin Hcl | 94 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 28 |
| Famotidine | Famotidine | 89 | 22 |
| Ozempic | Semaglutide | 86 | 20 |
| Trazodone Hcl | Trazodone Hcl | 86 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 19 |
| Montelukast Sodium | Montelukast Sodium | 74 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 70 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 23 |
| Farxiga | Dapagliflozin Propanediol | 67 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 20 |
| Baclofen | Baclofen | 62 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 20 |
| Mometasone Furoate | Mometasone Furoate | 61 | suppressed |
| Allopurinol | Allopurinol | 59 | 11 |
| Eliquis | Apixaban | 58 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 19 |
| Meloxicam | Meloxicam | 54 | 18 |
| Mirtazapine | Mirtazapine | 54 | 14 |
| Trulicity | Dulaglutide | 52 | 18 |
| Losartan Potassium | Losartan Potassium | 51 | 22 |
| Methocarbamol | Methocarbamol | 51 | 20 |
| Carvedilol | Carvedilol | 50 | 18 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Buspirone Hcl | Buspirone Hcl | 49 | 12 |
| Hydrocortisone | Hydrocortisone | 48 | 18 |
| Potassium Chloride | Potassium Chloride | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 47 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 45 | 13 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 43 | suppressed |
| Linzess | Linaclotide | 42 | 14 |
| Lidocaine | Lidocaine | 41 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | 11 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Omnipod Classic Pods (Gen 3) | Insulin Pump Cart,cont Inf,rf | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 12 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Prednisone | Prednisone | 28 | 21 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 28 | 11 |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 25 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Naproxen | Naproxen | 26 | 13 |
| Rybelsus | Semaglutide | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Zafirlukast | Zafirlukast | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Menest | Estrogens,esterified | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $287.41 · 15 records | GlaxoSmithKline, LLC. | Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, JOURNAVX, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error